Volume 8, Issue 3 (10-2024)
EBHPME 2024, 8(3): 227-234 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Lembris Noah J, Tesha N, Mugambage Ruhago G. Economic Burden of Sickle Cell Disease at Tertiary Health Facilities in Tanzania: Financial Impact on Patients at Muhimbili National Hospital. EBHPME 2024; 8 (3) :227-234
URL: http://jebhpme.ssu.ac.ir/article-1-515-en.html
URL: http://jebhpme.ssu.ac.ir/article-1-515-en.html
Department of Community Dentistry, Muhimbili National Hospital, MUHAS, School of Dentistry, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania , joshuanoah98@gmail.com
Abstract: (168 Views)
Background: Sickle cell disease (SCD) affects thousands in Tanzania, causing high healthcare costs and economic burden. This study estimates the annual cost of SCD care for patients at Muhimbili National Hospital.
Methods: This descriptive, cross-sectional study was conducted from June 2021 to May 2022 at Muhimbili National Hospital, Tanzania. A systematic sampling method was used to select 207 patients. Data were collected through structured interviews. Direct cost was also obtained from individual perspective and indirect costs were assessed using the Human Capital Method. Finally, data processing was done in Microsoft Excel, and analysis was performed using SPSS version 20.
Results: A total of 207 patients participated, with 91.3% under 18. The average annual cost of SCD care was TZS 847,186.01 (USD 367.62), with direct costs accounting for 76.4%. Medications, tests, and consultations were the major contributors to these costs (48%), and health insurance reduced costs by 64.4%.
Conclusion: SCD in Tanzania creates a significant financial burden, primarily due to direct medical costs, along with indirect costs like lost productivity. Addressing this requires better health insurance access, reduced indirect costs, and improved healthcare infrastructure.
Methods: This descriptive, cross-sectional study was conducted from June 2021 to May 2022 at Muhimbili National Hospital, Tanzania. A systematic sampling method was used to select 207 patients. Data were collected through structured interviews. Direct cost was also obtained from individual perspective and indirect costs were assessed using the Human Capital Method. Finally, data processing was done in Microsoft Excel, and analysis was performed using SPSS version 20.
Results: A total of 207 patients participated, with 91.3% under 18. The average annual cost of SCD care was TZS 847,186.01 (USD 367.62), with direct costs accounting for 76.4%. Medications, tests, and consultations were the major contributors to these costs (48%), and health insurance reduced costs by 64.4%.
Conclusion: SCD in Tanzania creates a significant financial burden, primarily due to direct medical costs, along with indirect costs like lost productivity. Addressing this requires better health insurance access, reduced indirect costs, and improved healthcare infrastructure.
Keywords: Sickle Cell Disease (SCD), Healthcare costs, Tanzania, Economic burden, Muhimbili National Hospital, Patient costs
Type of Study: Original article |
Subject:
Health Economics
Received: 2024/12/18 | Accepted: 2024/10/28 | Published: 2024/10/28
Received: 2024/12/18 | Accepted: 2024/10/28 | Published: 2024/10/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
